SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ELN Analysis & Videos »
ELN: Bull or Bear?
Biotech no longer a safe haven: Elan (ELN) falls on hard times
ELN
+6.37%
in
344 days
Filed under: Pfizer (PFE), Newsletters, Merck and Co (MRK), Stocks to Sell  It's been a tough year for many industries -- there's no denying it. Retailers of all stripes, oil companies, construction firms, financials, basic materials companies -- you name it, it's down.
So, are there any safe havens? Historically, in times of economic uncertainty the pharmaceutical industry, along with consumer staples, is often the "go to" place where, at a minimum, you can count on a nice dividend yield to shield your portfolio from gigantic losses. Not anymore. <>In this downturn even stalwarts such as Merck (...
|
Biogen Reports Another PML Case in Tysabri Patient
ELN
|
|
|
+3.11%
in
387 days
<> 
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
|
Biogen Reports Another PML Case in Tysabri Patient
ELN
|
|
|
+0.00%
in
3 hours
(closed on 10/30/08)
<>
After the market close, Biogen (BIIB) filed an 8-K with the SEC reporting a new case of the potentially fatal brain disease known as PML or progressive multifocal leukoencephalopathy in a patient receiving their multiple sclerosis [MS] drug Tysabri, adding to the two new cases which were reported previously in July. Biogen is currently trading down by about 15% after hours while marketing partner Elan (ELN) is down by about 25% as of 5:15 PM. The news adds more uncertainty to Tysabri, which was removed from th...
|
Clarity on Tysabri Makes Elan and Biogen a Buy
ELN
|
|
|
-48.77%
in
441 days
<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
|
Clarity on Tysabri Makes Elan and Biogen a Buy
ELN
|
|
|
-50.31%
in
53 days
(closed on 10/29/08)
<> The FDA has published a table with the names of products and potential signals of serious risks and/or new safety information identified for these products during 1Q08 in the AERS database. The FDA notes that patients should not stop taking these medications and should consult their prescriber with any questions as the agency will investigate each of the claims further before taking action or issuing more definitive statements on the reported concerns. Some highlights from this table of produ...
|
Biogen (BIIB): A 'dirt cheap' biotech bet
ELN
-50.56%
in
453 days
Filed under: Newsletters, Stocks to Buy "If you want to buy a great company dirt cheap, think Biogen Idec (NASDAQ: BIIB)," says biotech expert Michael Shulman. Here's an update from ChangeWave Biotech Investor. "Biogen recently got hammered on 'bad' news that wasn't actually so bad. BIIB and partner Elan (NYSE: ELN) reported that two MS patients, out of 31,800 currently receiving Tysabri, developed a rare brain malady called PML. <>"It's important to note, here, that the two companies had predicted that one in 1000 cases could develop PML and the FDA let the drug come to market with this unders...
|
Biogen-Idec, Elan: Panic Selling Creates Interesting Opportunity
ELN
-39.97%
in
467 days
In July, Biogen-Idec (BIIB) and Elan (ELN), who co-market the multiple sclerosis drug Tysabri, announced two new cases of PML, a potentially deadly side effect. The stocks sold-off almost entirely. Biogen-Idec lost about 30% of its market share while Elan has lost over two thirds of its value.
 I had previously recommended shares of Biogen-Idec right after the buyout rumors vanished and the stock was trading around 54. I had based that recommendation on the potential success of Tysabri.
|
Elan is way down and I'm buying
ELN
|
|
|
-43.20%
in
473 days
Today's stock selection:
ELN Elan
žInspired by:
Elan is way down and I'm buying http://articles.moneycentral.msn.com/Investing/StrategyLab/Rn...
I'm buying drug maker Elan ( ELN , news , msgs ) even though it is down more than 60% in the last three days. Here's why: Alzheimer's test results: Pass or fail? The first big drop came after the markets closed last Tuesday, when Elan detailed the results of its Phase 2 trial for bapineuzumab, a potential new drug for Alzheimer's disease. The company had previously announced that the Phase 2 trial did ...
|
Elan: Actionable Buy Call
ELN
-66.17%
in
479 days
Leerink Swann is out defending Elan (ELN) saying they are making no changes to their valuation of ELN shares and view any weakness today as a buying opportunity. The harsh sell off in the stock that could occur today will likely be fueled by overblown expectations for the Phase II data and the difficulty in presenting a cogent analysis of a complex trial in a complex disease in a 12-minute presentation.
|
Tysabri gets initial apporval
ELN
|
|
|
+7.77%
in
13 days
(closed on 01/31/08)
Elan, one of Ireland's biggest pharma companies, has announced that it has gained approval to test it's Tysabri treatment for Multiple Sclerosis. If this drug is a success, it could mean up to 1.1BN additional revenue for Elan and partner company Biogen (source: http://www.forbes.com/feeds/ap/2008/01/17/ap4542688.html ). Here is the news story:
US approval for Elan’s Tysabri Go ahead for controversial drug to treat Crohn’s disease By Triona Doherty <> Athlone-based company Elan have been given the go ahead this week to market their drug Tysabri in the ...
|
ELAN a company with an idea.
ELN
|
|
|
-66.35%
in
851 days
Iam semi new to this whole stock market scene but since i was in 11th grade i have been watching Elan i own a nice amount of shares in the company and bought early in the 12's i always say to myself i should sell. Recently the stock climbed to the mid 22's Now its back in the 19's. Their drug Tysabri is a drug in which can be expected to generate more revenue then expense. In order for this company to soar over the other biotech stocks this drug must succeed. From the trials it has under gone so far it looks promising. BUY NOW before too late and do not let go until ur in the 30's.
|
Fundamental analysis
ELN
|
|
|
-55.47%
in
925 days
Tysabri (to reduce the probability of MS recuringr) is continuing to increase in usage after being taken off the market due to safety issues (deaths) when used with Avonex or immunosuppressive drugs. This is a potential billion dollar drug. Elan shares revenue with Biogen IDEC. On the horizon is the start of phase III trials of an Altzheimer drug with Wyeth. This drug could change the shape of Wyeth and Elan. So far, the safety and effectiveness seems ok although phase II results are not all out. This could be a 10 Billion per year drug.
|
People Bullish on ELN
People Bearish on ELN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
|
|
|
|
tanumoy
(+107.70% risk: conservative)
|
|
|
More Resources
|
About Elan Corp plc
- Answers.com
